Correction of perinatally lethal neurogenetic diseases requires efficient transduction of several cell types within the relatively inaccessible CNS. Intravenous AAV9 delivery in mouse has achieved development stage-specific transduction of neuronal cell types, with superior neuron-targeting efficiency demonstrated in prenatal compared with postnatal recipients. Because of the clinical relevance of the non-human primate (NHP) model, we investigated the ability of AAV9 to transduce the NHP CNS following intrauterine gene therapy (IUGT). We injected two macaque fetuses at 0.9 G with 1 Â 10 13 vg scAAV9-CMV-eGFP through the intrahepatic continuation of the umbilical vein. Robust green fluorescent protein (GFP) expression was observed for up to 14 weeks in the majority of neurons (including nestin-positive cells), motor neurons and oligodendrocytes throughout the CNS, with a significantly lower rate of transduction in astrocytes. Photoreceptors and neuronal cell bodies in the plexiform and ganglionic retinal layers were also transduced. In the peripheral nervous system (PNS), widespread transduction of neurons was observed. Tissues harvested at 14 weeks showed substantially lower vector copy number and GFP levels, although the percentage of GFP-expressing cells remained stable. Thus, AAV9-IUGT in late gestation efficiently transduces both the CNS and PNS with neuronal predilection, of translational relevance to hereditary disorders characterized by perinatal onset of neuropathology.
INTRODUCTION
Neurological diseases are among the most devastating of human ailments, because of both the burden of disability in survivors and the challenge of finding an effective therapy that specifically targets the CNS, without morbidity from invasive injection procedures. Neurogenetic disorders characterized at the molecular level are potential candidates for gene therapy, which may offer a curative treatment option where few exist currently, and where symptomatic or supportive therapies have limited utility. 1 CNS-directed gene therapy presents unique challenges not encountered in the treatment of somatic disease, chiefly accessing the target organ across a restrictive barrier; achieving efficient transduction across a range of neuronal cell types; and overcoming ontological differences in neuronal cell susceptibility to viral vectors. While visceral disease may be alleviated with postnatal enzyme replacement therapy, stem cell transplantation or gene therapy, neuronal cellular pathology is more difficult to reverse. 2 A number of monogenic diseases manifest neurologically during the perinatal period. In disorders such as Gaucher type-II (acute infantile neuronopathic disease), infantile neuronal ceroid lipofuscinoses, and mucopolysaccaridosis (MPS) types I, IIA and III, early-onset brain damage is extensive and irreversible, and contributes to early childhood mortality. Although enzyme replacement therapy offers some benefit, its widespread application has been hindered by inhibitor formation and prohibitive cost. 3 Moreover, access to the CNS is limited by the blood --brain barrier (BBB), a protective sheath of tight junctions between vascular endothelial and choroidal epithelial cells, which prevents para-cellular passage of all large and most small water-soluble molecules (400 --500 Da) from the peripheral circulation into the cerebrospinal fluid and brain. 4 --6 This protective function severely restricts clinical application of intravenous enzyme replacement therapy in Gaucher and other lysosomal storage diseases. 7, 8 Success of allogeneic hemopoietic stem cell transplantation in Hurler syndrome (MPS I) and global cerebral leukodystrophy is limited by the rate at which donor microglia and mononuclear cells traverse the BBB, 9 a slow process that continues for several months after engraftment. As arrest of neuropathogenesis and symptomatic improvement are evident only after repopulation of the CNS, hemopoietic stem cell transplantation has limited ability to reverse neuronal disease in infantile forms of enzyme deficiency disorders. 10 --12 Furthermore, animal studies suggest that non-damaged neurons contribute to recovery of neurological deficits in CNS disorders treated with gene therapy, and that a critical threshold of transgenic protein production must be met before phenotype improves. 13 These data suggest that in the treatment of severe neurogenetic diseases, the time of intervention relative to natural disease progression is critical if gene therapy is to successfully restore sufficient neuronal function. This argument is especially compelling with infantile forms of metabolic disease where cellular damage manifests before birth. 14 Candidate viral vectors have been evaluated in postnatal CNSdirected gene therapy. In murine models of MPS IIIA 15 and infantile neuronal ceroid lipofuscinoses, 16 intracerebral delivery of lentiviral and adeno-associated viral (AAV) vectors, respectively, resulted in moderate levels of transgenic protein expression in the brain and partial neurological improvement. Intracerebral delivery to the fetus is unlikely to be implemented clinically in view of limited accessibility and the likely yet unquantified risk of procedure-related damage. A vector that efficiently achieves global neuronal transduction when administered systemically is thus integral to any therapeutic strategy aimed at treating neurogenetic disorders through intrauterine gene therapy (IUGT). Recombinant AAV have been extensively investigated as gene transfer vehicles as they transduce both dividing and non-dividing cells, resulting in sustained transgene expression while persisting mainly in an episomal form. 17, 18 They are not known to cause human disease, an advantage over herpes-simplex viruses which have similarly demonstrated efficacy in transducing neurons. 19 Compared with AAV2, the more recently isolated and characterized serotypes 5, 6, 7, 8 and 9 show better efficiency, stability of transgene expression and tissue tropism, which may be more relevant to CNS disease. 17, 20 In particular, AAV9 shows widespread neuronal tropism comparable to AAV8 but with better transduction of the brain and other organs. 21, 22 Intravenously administered AAV9 has demonstrated efficacy in targeting the CNS and peripheral nervous system (PNS) 23, 24 but with age-related differences in transduction efficiency 25 and cell type transducibility, where an earlier development stage is associated with predominantly neuronal transduction in contrast to mainly astroglial transduction at a later developmental stage. 23, 24, 26 Investigation of the potential for AAV9-mediated IUGT in a developmentally-relevant fetal model is timely.
IUGT offers the possibility of instituting treatment early in the disease timeline. Ideally, this should be performed before irreversible damage has occurred 27 and during a window when undamaged neurons can be harnessed for transgenic protein production, increasing the chances of complete symptom reversal. 13 Emerging evidence confirms the ontological susceptibility of neurons and astrocytes to gene transfer. 23 --26 In addition, the BBB is most permeable during development, 28, 29 when central tolerance to transgenic products might be induced and a high vector-to-cell ratio achieved. 30, 31 Proof-of-principle cure using intracerebral AAV-mediated IUGT in a rodent model of MPS VII demonstrates the potential for prolonged therapeutic transgene expression in the CNS. 32 As there are significant differences in fetal development between rodents and humans, 33, 34 we investigated the ability of a single intravenous dose of AAV9 to transduce the nervous system in a preclinical fetal macaque paradigm of IUGT.
RESULTS
IUGT results in maternal viraemia and capsid-directed immune response To investigate the ability of self-complementary AAV9 (scAAV9) to transduce the CNS and PNS after IUGT in late-gestation primates, two fetal macaques at 0.9 G (E140, gestational duration 155 days) each received 1 Â 10 13 vector genomes (vg), equivalent to 3.3 and 4.0 Â 10 13 vg kg À1 (based on birth weight) of scAAV9 expressing green fluorescent protein (GFP) driven by a ubiquitous CMV promoter. Vector was administered into the intrahepatic vein under US guidance and both fetuses tolerated the procedure well. Maternal viraemia was observed following fetal injection (Figure 1a) , with a viral load of 1.8 vg ml À1 of plasma detected 5 min after injection, resolving by 24 h in the mother of #9001 (M01). Maternal viraemia in the mother of #9002 (M02) ranged between 0.2 and 2.6 vg ml À1 plasma, resolving by 72 h after injection. #9001 was delivered spontaneously and #9002 by caesarean section at 147 gestational days (Table 1) , a gestation selected for surgical delivery in this model to minimize the risk of prematurity-associated complications and stillbirth associated with spontaneous vaginal birth. Both infant --mother pairs demonstrated a positive anti-IgG immune response against the AAV9 capsid (Figure 1b) , which persisted for the duration of the experiment (14 weeks), and was notably more robust in the #9002 --M02 compared with #9001 --M01 pair, reflecting the greater and longer-lasting maternal viraemia. Injected offspring were killed at 6 and 14 weeks, respectively, after birth for analysis. Infants and mothers showed no adverse effects related to IUGT or direct vector administration during the short period of observation, such as immunotoxicity.
Vector bio-distribution, GFP expression and immune response We performed quantitative PCR to determine the degree of transduction in different organs. In all organs examined, vector copy number (VCN) was 2-to 3 log-fold lower at 14 weeks compared with the 6-week time point, during which time body weight doubled ( Table 1) . As shown in Figure 1c , VCN was 216 and 1.3 copies per cell in the CNS at 6 and 14 weeks, respectively, a reduction of over 99%. VCN declined even more (499.5%) in somatic organs, from 4549 to 17 copies per cell in the liver, and 1902 to 3 copies per cell in skeletal muscle.
To determine the degree of transgene expression, the quantity of GFP relative to total extracted protein was measured by ELISA. GFP levels in the CNS measured 9.1 ng mg À1 total protein at 6 weeks and 5.5 ng mg À1 at 14 weeks, a 40% decrease. In the liver and muscle, GFP expression decreased by 28% and 77%, respectively, between 6 and 14 weeks (Figure 1d ). When transduction efficacy in the two subjects was assessed by comparing GFP expressed per vector copy (Figure 1e ), we found this to be higher in all organs in #9002 compared with #9001, ranging from 3085 ng mg À1 total protein per vector copy in the CNS (44 times higher) to 249 ng mg À1 total protein per vector copy in the liver (189 times higher).
Widespread GFP expression throughout the CNS and PNS following IUGT Stereoscopic imaging revealed variable GFP expression throughout the CNS as seen in representative images of the cerebrum and cerebellum (Figures 2a and b) , brainstem (Figures 2c and d) , pituitary stalk and gland (Figures 2e and f) , and spinal cord (Figure 2g ). Clusters of GFP-positive cells were clearly evident on the surface of the dorsal root ganglia (Figure 2h , white arrows). Non-neuronal transduction was fairly extensive as evidenced by robust GFP expression in skeletal muscle (Figure 2i) , and in the heart and great vessels (Figure 2j) , and by moderate expression in liver parenchyma (bisected surface; Figure 2k ).
To determine the extent of transgene expression at the cellular level, immunohistochemistry for GFP was performed. This confirmed widespread transduction throughout the cerebral cortex. Compared with the absence of staining in the brain from an uninjected control macaque (Figure 3a) , neuronal GFP expression was observed in laminar layers I to VI (Figure 3b (Figure 3g ), particularly in the dorsal column (Figure 3h ). The retina showed positive staining in treated animals compared with the control (Figure 3i ) throughout the various cell layers from the rods and cones (Figure 3j , layer marked RC on the control), to the ganglion cell and optic nerve fibre layers (marked GC and ONF on the control; Figure 3i ).
Evaluation of cell specificity of AAV9 transduction in the CNS following intrauterine delivery To determine the specific cell types transduced by AAV9, sections of the brain and its derivatives were immunostained for GFP and counterstained with appropriate cell-specific proteins. Organ sections from a non-injected macaque were treated similarly and served as controls. Transduced neurons were identified by their morphology, and co-expression of GFP (in green) and the neuronal marker microtubule-associated protein 2 (MAP2) (in red). Vector delivery, maternal viraemia and immune response. Following intrauterine delivery of AAV9, both mothers showed evidence of viraemia. In the mother of #9001 (M01), 1.8 vg ml À1 of plasma was detected 5 min after the procedure but had resolved by 24 h. In M02, maternal viraemia remained detectable at up to 2.6 vg ml À1 of plasma at 48 h and resolved by 72 h (a). Infants and mothers subsequently developed an anti-IgG immune response to the vector capsid present for up to 14 weeks (b), with the stronger response seen in the #9002 --M02 pair. Absorbance at 490 nm on the y-axis indicates intensity of colour change in spectrophotometry, which correlates with IgG levels. VCN was 99% lower in all organs in #9002 compared with #9001 (c). GFP production was lower by 41% in the CNS, 28% in the liver and by 77% in skeletal muscle (d). Efficacy of transgene expression was determined by the ratio of GFP produced per vector copy (e) and was markedly higher in #9002, ranging from 3085 ng mg À1 total protein per vector copy in the CNS (44 times higher than in #9001) to 249 ng mg À1 total protein per vector copy in the liver (189 times higher than in #9001). --p) , the majority of astrocytes were not transduced and are clearly visible in between GFP-positive neurons. In the cerebrum, the typical 'fried egg' morphology of oligodendrocytes as seen in Figure 3d was not readily recognizable. Oligodendrocytes were instead identified based on O4 staining, eccentric nuclei and the paucity of processes (Figures 5q --t) . In the cerebellum, occasional cells co-labelled with O4 were observed in the granular layer (Figures 5u --x) .
GFP
To quantify GFP-expressing neurons and glial cells in the CNS, we counted GFP-co-labelled and unlabelled cells ( Figure 6 ), and found that, among MAP2-positive neurons, transduction efficacy was 67% and 96% in the cerebrum, 92% and 97% in the cerebellum, and 86% and 90% in the spinal cord in #9001 and #9002, respectively. GFP transduction of ChAT-positive neurons was observed in the cerebrum (35 and 66%), cerebellum (91 and 90%) and spinal cord (91 and 75%) in the respective animals. O4-positive cells showed variable levels of transduction, with GFP expression in 82% and 77% in the cerebrum, 41% and 22% in the cerebellum, and 90% and 60% in the spinal cord of #9001 and #9002, respectively. Astrocytes showed the least efficient degree of transduction, with only 13 --34% of GFAP-positive cells co-expressing GFP. There was no difference in the transduction efficiency of any cell type between the two subjects.
Finally, we investigated the transduction of neural progenitors by co-staining for nestin, a neural stem cell marker. Co-labelled cells with the morphology of neuronal soma were observed throughout the cerebral cortex (Figures 7a --d) . In the cerebellum, double-positive cells were found in the Purkinje and molecular layers that had the morphology of Purkinje cells (Figures 7e --h, white arrows), and possibly Golgi (small white arrowheads) and basket cells (red arrows).
Evaluation of transgene expression in the PNS Transduction of neurons and glia in the PNS was examined by co-staining cells for GFP and the relevant cell marker. GFP expression was demonstrated in the dorsal root ganglia by neurons co-expressing MAP2 (Figures 7i --l) and GFAP-positive astrocytes (Figures 7m --p) . Myelin sheaths of neurons were positive for O4 but GFP expression was limited to the neuronal axons ( Figures  7q --t) . Ganglion cells co-expressing GFP and MAP2 were observed in the submucosal Meissner's plexus (Figures 7u --x) and myenteric Auerbach's plexus (Figures 7y --AB) in the intestine. In the retina, Figure 2 . GFP expression in whole organs by stereoscopic imaging. A variable degree of GFP expression was observed upon examination of the whole cerebrum and cerebellum (a, b, control inset), the brainstem (c, ventral view; d, dorsal view), pituitary stalk (e), and gland (f, high-power inset) and the spinal cord (g, ventral view, high-power inset). Clusters of strong fluorescence were observed on the surface of the dorsal roots (h, white arrows). Strong GFP expression was also noted in the skeletal muscle (i), heart and aorta (j), and from the liver parenchyma (k, cut surface, control inset). Images shown are representative of both animals.
neuronal cell bodies in the ganglion layer (Figures 7AC --AF, red arrows), the inner nuclear layer (Figures 7AG --AJ , red arrows), and the photoreceptor outer segments and cell bodies co-expressed MAP2 and GFP ( Figure 7AJ , white arrow). Extra-neuronal GFP expression was noted in the outer plexiform and nuclear layers.
DISCUSSION
A recent series of studies of the mechanisms of AAV9 transduction reflect the keen interest in the therapeutic potential of this vector to target the CNS, 23 --26,35 --37 heart 38,39 and lung. 40 However, important limitations remain to be addressed. The ability of this vector to cross the BBB and transduce neurons is clearly dependent on the age of the recipient, the route of administration and the presence of neutralizing antibodies. Significant extraneurological spillage may complicate clinical therapy owing to ectopic transgene production, which in enzyme deficiency syndromes may need to be tightly regulated. Engineering the vector to overcome these limitations will be important in achieving successful clinical translation.
We have proposed an intrauterine approach to circumvent the above issues in prenatally diagnosed neurogenetic diseases, and demonstrate some of the main advantages of such a strategy in this study. First is the global neuronal transduction demonstrated, which will be useful to counteract the widespread neuronal loss and cortical atrophy seen in the neuronal lipidosis phenotype of lysosomal storage disease, such as MPS. We report transduction in the range of 67 --97% for neurons and 35 --91% for motor neurons. The moderate-to-efficient transduction of oligodendroglia we observed (22 --90%) may also be useful for treating the leukodystrophy phenotype of lysosomal storage disease, such as Krabbe disease. An additional benefit is the transduction of neural progenitor/stem cells in the cerebrum and cerebellum, which are more abundant at an earlier stage of development, a factor, which may contribute to lifelong transgene expression. We achieved this through intravenous delivery, using a minimally invasive technique that obviates the risk of iatrogenic damage inherent in intracranial or intrathecal approaches. Second, this study demonstrates the ontological advantages of gene transfer in the earlier stages of development. We previously reported a marked difference in expression pattern in mice with both single-strand (ss) and self-complementary (sc) AAV9, where distinct neuronal predominance was seen with fetal delivery in contrast to the astrocyte predominance seen with neonatal delivery. 24 Ontological differences in transgene expression are further underscored by findings in neonatal and adult mice, 23 and cats. 26 In comparison with AAV9 studies of the postnatal non-human primate (NHP), we have shown a more extensive neuronal expression pattern with the intrauterine approach using 3.3 --4.0 Â 10 13 vg kg
À1
. Kaspar and co-workers observed consistent and robust motor neuron transduction throughout the spinal cord and dorsal root ganglia in postnatal cynomolgus macaques following intravascular delivery of 1 --3 Â 10 14 vg kg À1 between 1 and 90 days. However, despite the higher dose, the majority of targeted cells were glial rather than neuronal. 25, 37 Gray et al. 41 also observed mostly astrocytic transduction with considerably lower neuronal expression following an intravascular dose of 9.5 Â 10 12 vg kg À1 in juvenile NHP. In light of available murine studies, their lower expression is probably more a reflection of CNS maturity at the time of vector administration rather than dose, as Gray et al.'s dose was sufficient for high levels of transduction in peripheral organs. These studies collectively point towards a prenatal window for achieving efficient neuronal transduction, which is lost in early neonatal life. Another advantage of early gene transfer is the lower risk of immune-mediated loss of expression. This was thought to contribute in part to the lower CNS transduction in young macaques, 41 and is an important consideration as an estimated 33.5% of the human population has pre-existing seropositivity to AAV9. 42 The fetuses in our study were injected at 0.9 G when clearly immune-competent, and thus a capsid-directed humoral response was observed. Nevertheless, GFP expression was not neutralized in these animals. Ideally IUGT would be performed during the immune-naïve phase of development, which in the Figure 4 . (Continued).
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human and NHP is between 0.3 and 0.4 G. 43, 44 In practice, this will depend on how early in gestation the diagnosis is made and whether preparations can be made for gene transfer within a short time frame. Circulation in the human fetus can be accessed in the first trimester by ultrasound-guided techniques used for prenatal diagnosis, with a low fetal loss rate in experienced hands, 45 or through embryo-fetoscopy to facilitate visualization and fetal blood or tissue sampling from as early as 7 weeks of gestation. 46, 47 Thus it will be possible to treat a monogenic disease in the first trimester as soon as diagnosis has been confirmed and before acquisition of immune competence. 43, 48, 49 Notwithstanding their small scale, these experiments are important in demonstrating that significant CNS transgene expression can be still achieved even at late gestation, a clear advantage over postnatal gene transfer. Lastly, as the volume of vector production necessary to meet postnatal AAV dosage requirements presents a practical obstacle to clinical success, there is a stoichiometric advantage to fetal treatment at a far lower titre to achieve a therapeutic effect.
Although the potential to effect long-term therapeutic expression has yet to be investigated in the NHP model, studies with reporter transgenes in NHP 37 and therapeutic transgenes in rodents 26, 35 suggest that expression may be observed for at least 6 months after a single intravenous injection of scAAV9. We recently demonstrated therapeutic human FIX expression for almost 2 years following intravenous IUGT at 0.9 G with scAAV8 in the presence of persistent episomal and integrated forms of the vector genome. 50 In the current study, we were primarily interested in the ability of AAV9-mediated IUGT to transduce the fetal CNS, with identification of the cellular sub-types targeted. We did not interrogate the bio-safety profile of AAV9-mediated IUGT; however, we note the absence of early-onset severe complications from gene transfer, such as pregnancy loss or immunotoxicity. As our current investigation used an expression cassette based on the modified AAV2 backbone, similar to the expression cassette used in the earlier study, it is possible that there will be a low risk of vector genomic integration as seen previously with the use of AAV5 and AAV8, albeit in the context of a liver-directed approach. 50 Our findings illustrate the extent of neuronal targeting that can be achieved by delivering the vector in fetal life, which may be facilitated by the incompletely developed BBB and possibly by the early appearance of neuronal receptors compatible with AAV9 capsid proteins. In this study, both injected offspring showed transduction of the majority of Purkinje cells in the cerebellum and neurons, including motor neurons in the spinal cord, compared with the greater variation in neuronal transduction found within the cerebrum, suggesting that specific neuronal cell types may be more readily transduced than others. While this may be a function of the longer axonal processes in such cell types, their proximity to the BBB endothelium may also have a role, as mechanisms by which neurons are targeted by AAV9 in fetal and early neonatal life remain to be determined.
Our data also suggest that, while cellular VCN and protein generated per vector copy decreased over time owing to the dilutional effect of rapid infant growth on episomally maintained AAV (Table 1) , the percentage of each cell type expressing GFP remained stable over the period of observation. We speculate that this may be attributable to either the reporter transgene being shuttled from a transduced to an untransduced neuronal cell, or to protein expression arising from a minority of persistent vector copies. Recent studies examining the anatomical spread of neuropathology in Parkinson, Alzheimer and Huntington diseases point to intercellular spread of pathological protein aggregates.
--53
Figure 4. GFP expression in neurons co-labelled with MAP2 and ChAT. GFP and cell-specific protein expression were observed in the green and red channels, respectively, with co-expression shown as yellow in the merge (indicated by white arrows). All images were taken by confocal scanning microscopy at Â 60 magnification unless stated otherwise and are representative of both animals. GFP-expressing neurons were seen in the cerebral cortex (a --d), the Purkinje layer of the cerebellum (e --h) and the spinal cord (i --l). Transduced neurons expressing ChAT and GFP were observed in the cerebral cortex (m --p, Â 20 magnification), the Purkinje and granular layers (q --t), and the ventral horn of the spinal cord (u --x). All scale bars at 50 mm.
Proposed mechanisms of cell --cell communication include tunnelling nanotubes 54 and axon --dendrite interactions. 55 Our observations could reflect another potential benefit of this intervention, that is, active transport of a transgenic protein expressed by transduced neurons to adjacent untransduced neurons, thus contributing to the therapeutic effect. This will require exploration in further studies.
Although the VCN was markedly lower in #9002 compared with #9001, GFP expression was quantitatively similar, suggesting a more efficiently expressed transgene per VCN in #9002. This may Figure 5 . (Continued).
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reflect sustained efficient production of GFP from integrated vector copies or persistent episomes in a small population of cells susceptible to stable transduction with this vector cassette, as described previously for AAV2. 56 Alternatively, the small number of animals analysed with their inherent biological variation may account for the differences observed. Another possible explanation for this trend is that the maternal anti-AAV9 antibodies observed in M02 immediately after IUGT may have crossed the placenta and limited the degree of cellular transduction in #9002. Retrospective examination of plasma collected from M02 and her offspring from a previous pregnancy (not injected with AAV9) revealed low-level anti-AAV9 antibodies in both Figure 5 . GFP expression in astrocytes and oligodendrocytes. Astrocytes co-expressing GFAP and GFP were observed in the cerebrum (a --d), cerebellum (e --h), brainstem (i --l) and spinal cord (m --p). Oligodendrocytes co-labelled with O4 were observed in the cerebrum (q --t) and cerebellum (u --x). All scale bars at 50 mm. Figure 6 . Transduction efficacy of the various cell types in the CNS. Quantification of co-labelled cells was performed to assess transduction efficacy. In #9001 and #9002, transduction efficacy of MAP2-positive neurons was 67% and 96% in the cerebrum, 92% and 97% in the cerebellum, and 86% and 90% in the spinal cord, respectively. GFP transduction of ChAT-positive neurons was observed at 35 and 66% in the cerebrum, 91 and 90% in the cerebellum, and 91 and 75% in the spinal cord. O4-positive cells showed variable levels of transduction, with GFP expression at 82% and 77% in the cerebrum, 41% and 22% in the cerebellum, and 90% and 60% in the spinal cord, respectively. Transduction was least efficient in astrocytes as co-labelled cells constituted 13 --34% of GFAP-positive cells. There was no difference in transduction efficacy of the different cell types between subjects.
mother and infant. In the latter these decreased soon after birth consistent with transient circulating maternal antibodies (data not shown). In the current pregnancy, the mildly elevated anti-AAV9 level present in M02 prior to IUGT and the robust immune response after vector delivery may have in part contributed to the observed differences in offspring GFP expression at the time points examined.
The marked decrease in vector copies with ongoing growth is indeed one of the major factors limiting clinical use of AAV in growing subjects, 57, 58 particularly where lifelong expression of a transgenic protein is required. Although early IUGT for CNS diseases is still desirable temporally to mitigate intrauterine damage, several strategies may need to be considered to counteract loss of expression, as have been attempted with other Figure 7 . (Continued). 59, 60 administering an effective dose to transduce a critical mass of target cells 61, 62 and postnatal re-administration of the vector 63 in subjects who have been immune-tolerized by exposure during early gestation. 64 --67 Alternatively, use of transient immune suppression may allow re-administration of the same vector to animals which have been sensitized. 68 In addition to transduction in the CNS, we found evidence of neuronal transduction in the sensory-somatic PNS with GFP expression in the retina, and in the autonomic PNS with neurons in the Meissner's and Auerbach's plexuses in both the small and large intestine strongly expressing GFP. This broad specificity may find application in treating hereditary sensory and autonomic neuropathies, and in the context of fetal gene therapy, AAV9 may Figure 7 . (Continued).
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prove useful in disorders such as familial dysautonomia, which presents in infancy with hypotonia and defective swallowing, and can prove lethal through aspiration pneumonia. Because this neuropathy only has significant impact after birth, late-gestation IUGT with AAV9 expressing a therapeutic transgene may prove beneficial. Whether simultaneous transduction of neurons in the CNS and PNS will be of clinical benefit remains to be determined.
A similar consideration in applying AAV9 gene therapy is the spill-over effect that we observed onto extra-neuronal organs. In translating a gene therapeutic approach to the clinic, it may be beneficial to avoid ectopic production of the transgenic protein. 38, 40 Tissue-specific expression may be improved with vector engineering. 69 Extra-neuronal tissue transduction may be advantageous in the IUGT of some candidate neurogenetic diseases, in particular lysosomal storage disease characterized by prominent somatic manifestations, as this may allow neurological and nonneurological damage to be treated simultaneously. In light of the high transduction efficiencies achieved in the liver and spleen, AAV9 could be considered for gene therapy approaches for Gaucher, Niemann --Pick and Krabbe diseases, as well as certain MPS, particularly ones where currently established therapies such as hemopoietic stem cell transplantation are not applicable.
An interesting finding was the robust transduction in the eye, with the photoreceptor outer segments, cell bodies, inner and outer nuclear layers, and ganglionic layer strongly expressing GFP. A number of hereditary enzyme deficiency syndromes are associated with ocular manifestations, 70 and nearly half of the cloned human retinal disease genes are highly enriched in photoreceptors, many of which are involved in lipid and protein metabolism and transport. 71 Inherited retinopathies may result in phenotypic disease primarily manifesting as severe vision loss such as Leber congenital amaurosis, or be part of a wider syndrome with multi-organ pathology such as Bardet --Biedl syndrome and abetalipoproteinaemia. Although isolated retinopathy is best treated with intraocular gene delivery, 72 the systemic approach to gene correction may be preferable for pleiotrophic disorders involving the retina, particularly as AAV9-IUGT extensively transduced a number of viscera, including the heart, kidneys and intestines, as well as ciliated epithelia in several organs (data not shown). As Bardet --Biedl syndrome and abetalipoproteinaemia are characterized by congenital visceral abnormalities, 73 and spinocerebellar or dorsal column tract degeneration (which can be lethal in infancy), 74 a case could be made for fetal intervention.
In conclusion, this work demonstrates the ability of AAV9 to cross the BBB in a clinically relevant fetal NHP model when delivered intravenously by percutaneous ultrasound-guided injection, an established procedure in fetal medicine practice. 75 This transduced the vast majority of neurons in the CNS and PNS, including primitive neural progenitor cells. It is likely that this vector will find its most feasible clinical application when constructed with tissue-specific regulatory elements limiting the expression of a therapeutic transgene to the target cell types damaged by enzymatic dysfunction. Future development should now focus on engineering AAV9 with organ-specific expression cassettes, 38 re-engineered chimeras 76 or modifications to improve cell-specific binding, 40 to treat neurogenetic diseases which cause significant perinatal morbidity and/or early mortality.
MATERIALS AND METHODS

Animal welfare
Animal procedures were approved by and performed in strict accordance with the recommendations of the Institutional Animal Care and Use Committee (IACUC) at the National University of Singapore and Singapore Health Services Pte Ltd (IACUC 2009-SHS-512). All in vivo work was conducted at the SingHealth Experimental Medicine Centre, accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Infants were delivered surgically where possible and hand-reared. Surgical procedures were conducted on isofluorane-anaesthetized animals, with every effort taken to minimize suffering. Animals were killed for analysis by isofluorane general anaesthesia, with an overdose of pentobarbitone, cardiac puncture and saline perfusion, in accordance with the recommendations of the Weatherall report. 77 Vector production A self-complementary AAV2/9-CMV-eGFP was obtained from the Penn Vector Core, University of Pennsylvania (Philadelphia, PA, USA).
Animal experiments
Potential dams were screened prior to time-mating to exclude those with pre-existing anti-AAV9 antibodies in order to avoid immune rejection of the injected vector. One female Macaca fasicularis had mildly elevated anti-AAV9 antibodies at screening whereas the other was seronegative. They were time-mated, and their pregnancies were dated and monitored by Figure 7 . Progenitor cells and transduction in the PNS. GFP and cell-specific protein expression were observed in the green and red channels, respectively, with co-expression observed as yellow in the merged channel (indicated by white arrows). All images were taken by confocal scanning microscopy at Â 60 magnification unless stated otherwise and are representative of both animals. Putative progenitor neuronal cells co-expressing GFP and nestin were observed in the cerebrum (a --d) and cerebellum (e --h). In the PNS, transduced neurons were observed in the dorsal root ganglia (i --l), as were transduced astrocytes (m --p). Myelin sheaths expressing O4 did not express GFP (q --t); this was limited to axons. Transduced neurons were observed in the submucosal Meissner's (u --x) and Auerbach's plexus (y --AB) in the small intestine. In the retina, GFP-expressing neurons were observed in the ganglion cell layer (AC --AF; RC, rods and cones; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GC, ganglion cell layer), inner nuclear layer (AG --AJ, red arrows) and photoreceptor layer (AJ, white arrow). All scale bars at 50 mm.
ultrasound. At 0.9 G (E140 of a 155-day gestation) IUGT was performed as reported previously. 50 A dose of 1 Â 10 13 vector genomes of scAAV2/9-CMV-eGFP in a total volume of 4 ml was infused slowly into the fetal intrahepatic vein. Two live infants were delivered 1 week later, the first following a planned caesarean section under general anaesthesia (#9002) and the second vaginally after spontaneous labour intervened before the planned surgical delivery (#9001).
At predetermined time points of 6 and 14 weeks after birth, treated infants were killed as described above and perfused with cold 1% paraformaldehyde in phosphate-buffered saline (PBS). Full-body necropsies were performed for analyses of vector bio-distribution and transgene expression. The cerebrum, cerebellum, midbrain, brainstem, spinal cord and dorsal roots were removed, placed in 1% paraformaldehyde at 4 1C overnight, and evaluated for transgene expression.
Maternal viraemia
To assess transplacental trafficking of the vector, maternal blood was sampled before and after IUGT, and cell-free DNA was extracted from maternal plasma as described previously. 50 Five microlitres of digested plasma were used for quantitative real-time PCR in a 25-ml reaction consisting of 1 Â SYBR Green Master Mix (Applied Biosystems/Life Technologies, Carlsbad, CA, USA) and 900 nM each of a forward primer 5 0 -CATGGTGATGCGGTTTTG-3 0 and a reverse primer 5 0 -CCTCACGACCAA CTTCTG-3 0 (amplifying a 333-bp sequence of the 3 0 -end of the CMV promoter, and the vector backbone between the promoter and the downstream transgene sequence). Cycling conditions were as follows: 95 1C for 5 min, and 55 cycles of 95 1C for 10 s and 61 1C for 30 s. Viral load was expressed as copies per microlitre of maternal plasma. Plasma from uninjected monkeys and the pre-IUGT sample served as the negative external and internal controls. The sensitivity of the assay was 1 viral particle per 5 ml of plasma.
Vector bio-distribution Genomic DNA was extracted from snap-frozen tissue as described previously. 50 A 15-ng weight of genomic DNA was subjected to quantitative real-time PCR using the primers and conditions above. A 52-bp region of the macaque b-actin gene was amplified using the forward primer 5 0 -TCCTGTGGCATCCACGAAA-3 0 and the reverse primer 5 0 -CCACGT CACACTTCATGATGG-3 0 as a loading control. Vector copies were expressed per diploid genome (6.6 pg of DNA, VCN per cell, VCN) and the calculated limit of detection was 1 vg per 227 diploid genomes. Naïve DNA from untransduced NHP served as negative controls.
GFP quantification assay
Enhanced GFP expressed by various tissues was quantified by ELISA. The primary antibody (mouse monoclonal anti-GFP; Abcam, Cambridge, UK) was diluted 1:10 000 in bicarbonate buffer (0.015 M Na 2 CO 3 , 0.035 M NaHCO 3 ) and 100 ml was added to each well of a 96-well plate (Maxisorb; NUNC, Rochester, NY, USA) overnight. After washing with PBS containing 0.05% Tween-20 (PBST), plates were in turn incubated with 300 ml per well of blocking buffer (1% bovine serum albumin in PBS), 200 mg protein per well of sample or standards (serial dilutions of GFP starting at 4000 pg per well), 100 ml per well of a biotin-conjugated secondary antibody (1:5000 in blocking buffer; Abcam) and 100 ml per well of streptavidin --HRP (1:20 000 in blocking buffer), incubating every stage at 37 1C for 1 h. A 100-ml volume per well of tetramethylbenzidine was incubated at room temperature for 10 min, avoiding exposure to direct light. Colour development was terminated using100 ml per well of 2.5 M H 2 SO 4 and absorbance was read at 450 nm.
Stereoscopic imaging of whole organs for GFP expression
Exterior surfaces of whole organs and internal surfaces (after bisection) were imaged with the Nikon Stereoscopic Zoom microscope SMZ1500 with epifluorescent attachment at magnifications ranging from Â 0.75 to Â 11.25. The baseline exposure time for each organ was set by imaging control specimens harvested from non-treated animals and processed in the same manner.
Immunohistochemistry for GFP expression Paraformaldehyde-fixed whole organs and tissue samples were transferred to 10% formalin overnight, fixed in paraffin and layered onto poly-lysine slides at 4-mm sections. Brains were cut coronally into six segments from frontal to occipital lobes, and each segment was sectioned for analysis. The cerebellum, brainstem and spinal cord were dissected and sectioned individually, with both coronal and sagittal sections of the spinal cord analysed in series to maintain their rostral --caudal sequence. Antigen retrieval was performed by boiling in an antigen unmasking solution (Vector Labs, Peterborough, UK) following the manufacturer's instructions at 95 1C for 30 min. Serum blocking buffer was applied for 30 min (5% bovine serum albumin, 5% normal goat serum in PBST with 0.2% Triton-X; Vector Laboratories and Roche, Basel, Switzerland) at room temperature.
For diaminobenzidine chromogen staining of brain sections, endogenous peroxidase in samples was blocked by incubating in a 3.5% solution of 30% hydrogen peroxidase in methanol for 30 min minutes prior to serum block. After serum block, slides were incubated overnight at 4 1C with a rabbit polyclonal anti-GFP antibody (ab290; Abcam) at 1:5000 in 10% goat serum in PBST. Biotinylated goat anti-rabbit IgG (Vector Labs; 1:200 in 10% goat serum) was added for 30 min at room temperature. The Vectastain Elite ABC kit was applied for 30 min at room temperature, with the ImmPACT diaminobenzidine substrate kit (Vector Labs) used to develop staining, followed by haematoxylin counterstaining, xylene wash and imaging using an Olympus BX61 microscope.
For fluorescent double immunostaining, following serum block, sections were incubated overnight at 4 1C with a rabbit polyclonal anti-GFP antibody (1:500; Abcam) and a second tissue-specific antibody in 10% serum blocking buffer. These were anti-MAP2 at 1:200, anti-neurofilament M at 1:200, anti-O4 at 1:200, anti-GFAP at 1:200, anti-ChAT at 1:100 and anti-nestin at 1:100 (all from Millipore, Billerica, MA, USA). Following two washes in distilled water, sections were incubated with the secondary antibodies goat anti-rabbit (Alexa Fluor 488; Invitrogen, San Diego, CA, USA) and goat anti-mouse (Alexa Fluor 594; Invitrogen), both at 1:100 (in 10% serum blocking buffer), at room temperature for 30 m, and mounted with 4',6-diamidino-2-phenylindole (HT-1500; Vector Laboratories). Negative controls consisted of non-transduced NHP tissue sections treated in the same manner. All images were captured with an Olympus Fluoview FV1000 scanning confocal microscope.
Quantification of transduced cell types
Three double-immunostained slides were randomly selected from the cerebrum (anterior, middle and posterior), cerebellum, midbrain and spinal cord (rostral, middle and caudal thirds) of both animals. Slides were imaged in quadrants at Â 20 magnification, with one image per quadrant used for counting. Neurons, motor neurons, astrocytes and oligodendrocytes were identified based on typical morphology and expression of MAP2, ChAT, GFAP and O4, respectively (imaged in the red channel), and recounted with GFP (green channel) superimposed to identify co-labelled cells. Mean transduction efficacy was derived per slide and expressed as a percentage of the total neuron, motor neuron, astrocyte and oligodendrocyte count. A median of 144 cells were counted per slide (range 52 --387).
Immune response
Anti-AAV9 capsid antibody response following IUGT was assessed by ELISA as described previously. 50. Briefly, 96-well plates (NUNC) were coated overnight with 5 Â 10 8 AAV particles, blocked, incubated with sample or control plasma (diluted 1:50), goat anti-Rhesus IgG (1:4000 dilution; Southern Biotech, Birmingham, AL, USA) and the OPD peroxidase substrate (SIGMA FAST P9187), with the colour reaction quenched with 3 M HCl. Maximum UV absorption was measured at 490 nm, normalized to the baseline (negative control, plasma from an uninjected macaque fetus) and expressed as a ratio of the positive control (plasma from a seropositive macaque).
Statistics
Non-parametric data were analysed by Mann --Whitney U-test. A P-value of o0.05 was considered significant.
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